Adriamycin-based
chemotherapy is commonly used for malignant
soft tissue sarcoma including
myxoid liposarcoma. However, in the case of unavailability or failure of the
adriamycin-based regimen,
trabectedin or
eribulin can produce a good antitumor effect for
myxoid liposarcoma. We relate the experience of a 64-year-old female with
myxoid liposarcoma, who noticed a nodule on her left thigh and visited our institute. At initial presentation, the
tumor was 18.7 cm in diameter, and the magnetic resonance imaging (MRI) showed a malignant lipomatous
tumor with a myxoid component. We recommended that she undergo treatment; however, she refused. Three years later, the
tumor had grown larger, so she finally decided to undergo treatment. A needle biopsy revealed a
myxoid liposarcoma. The
tumor massively involved the neurovascular structures; we thus determined that hip
disarticulation was inevitable. Two years later,
metastases in the right thigh, left lung, right ileum, and abdominal space were pointed out and
chemotherapy was initiated.
Adriamycin was unusable due to cardiac dysfunction, so
trabectedin was administered; however, the
tumors progressed.
Eribulin was subsequently started and has been considerably effective for more than 2 years without severe adverse effects. In conclusion, we experienced a case showing the remarkable and long-lasting effect of
eribulin against
trabectedin-resistant
myxoid liposarcoma.